MRPL18

Across TCGA pan-cancer cohorts, MRPL18 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MRPL18 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MRPL18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRPL18 expression acts as an unfavorable survival marker.

KIRP, READ, and ESCA are the cancer types where MRPL18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.016	0.920	<.001	12	view →
READ	OS	Median	II,III,IV	0.187	0.644	.023	12	view →
ESCA	OS	Median	All	0.080	0.701	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
KIRC	OS	Median	All	0.263	0.810	.015	10	view →
COAD	OS	Median	III,IV	0.168	0.691	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MRPL18–KIRP (DFS)

Open the KIRP breakdown →